


EscharEx[®]

Next-Generation
Enzymatic Debridement
for Chronic Wounds



New SOC¹ Candidate


Modalities by Efficacy and Complexity



¹ standard of care


Superior Outcomes²

Debridement



²Dove et al. 2025; *Wound*

Wound Bed Preparation



Rapid Debridement and Facilitation of Wound Closure



- Investigational drug containing a sterile mixture of proteolytic enzymes
- Debrides chronic wounds within 4-8 applications
- Easy to use topical application in all patient settings
- Reduces bacteria and biofilm
- Promotes granulation tissue
- Demonstrated superiority over SANTYL[®]
- Aligns with treatment workflows & reimbursement landscape
- De-risked program; based on 3 successful Phase II trials
 - Ongoing Phase III trial for VLU
 - DFU trial planned H2 2026
 - Pressure ulcers (PU), Investigator-Initiated Trial (IIT) planned H2 2026
- Strategic research collaborations with Mölnlycke, Solventum, Medline, Essity, B. Braun, Coloplast, Convatec and MIMEDX